Quest Magazine

Grants Support Study of New Genes, New Drug Discovery Strategies for ALS

Twelve new grants totaling $3.6 million have been awarded in support of research studies that will explore the causes of, and potential treatments for, amyotrophic lateral sclerosis (ALS).

LGMD2A Registry Seeks Participants

A recently opened global registry— a database of patient information — is seeking people with the type 2A form of limb-girdle muscular dystrophy (LGMD2A), a form of LGMD that results from a deficiency of the calpain 3 protein.

Diagnostic Blood Test for ALS Under Development

Development is under way of a blood test that may help doctors rule in or rule out a diagnosis of amyotrophic lateral sclerosis (ALS).

FDA To Hold ALS Public Hearing: Input Encouraged by Feb. 8

The Food and Drug Administration (FDA) will hold a public hearing on amyotrophic lateral sclerosis (ALS) on Feb. 25. It will be open to individuals and caregivers affected by ALS, ALS clinical research experts, and those with strong opinions about the needs of the ALS community.

Summer International Affairs Internships Available in Washington

If you are a college student or recent graduate with a disability and are interested in a career in international affairs, there’s a new internship program launching this summer in Washington, D.C.  However, if you want to be considered, you’ll need to hurry — the online deadline is February 18.

ALS Research Briefs: Stem Cell Therapy

Development of stem cell therapy to treat amyotrophic lateral sclerosis (ALS) continued with two studies in mice, one by an Israeli biotech company and one by an Italian research team.

Survey Open for People with IBM

A survey of people with inclusion-body myositis (IBM) is being conducted by A. David Paltiel, a professor of public health (health policy) and management at Yale University, with colleagues there and at the Myositis Association.

MDA Establishes Myotonic Dystrophy Clinical Research Network

MDA has launched a new, five-center clinical research network focused on type 1 and type 2myotonic muscular dystrophy (MMD1 and MMD2, also known as DM1 and DM2), with the principal goal of preparing for testing of new MMD treatments as they become available.

Spice for CMT1B? Curcumin Shows Benefit in Research Mice

Mice with a disorder resembling the type 1B form of Charcot-Marie-Tooth disease (CMT) benefited from treatment with either of two forms of oral curcumin, a component of the spice turmeric, according to researchers supported in part by MDA.

Friedreich’s Ataxia: Drug Enters Phase 2b Clinical Trial

Edison Pharmaceuticals has launched a phase 2b clinical trial of its experimental drug EPI-743 in adults with Friedreich's ataxia (FA) to assess whether the drug has positive effects on visual function, neurological and neuromuscular function, and disease-associated biomarkers.

Pages